Business
Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)
Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R).
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)\n \n \nMarina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)\n\nCompany to narrow its business focus to pain and hypertension; Company plans to sell or divest the oligonucleotide therapeutic assets\n\n \n CITY OF INDUSTRY, CA--(Marketwired - Jun 26, 2017) - Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that Erik Emerson will join the company in the newly created role of Chief Commercial Officer, effective immediately. \n Mr. Emerson most recently served as the President and Chief Executive Officer of Symplmed Pharmaceuticals, which he had founded in 2013. He had led Symplmed to the submission, approval and commercial launch of Prestalia®, and to the eventual sale of such assets to Marina Biotech in June 2017. He also spearheaded the development and launch of Symplmed's DyrctAxess technology, a patented software designed to manage prescription fulfillment and patient monitoring. DyrctAxess has demonstrated a significant impact on patient conversion to treatment, long-term compliance and overall patient retention. Prior to founding Symplmed, Mr. Emerson served as the head of Commercial Development at XOMA from 2010 to 2013; and as Director of Marketing at Gilead Sciences from 2007 to 2010. He began his career at King Pharmaceuticals in sales, sales training and marketing. Mr. Emerson graduated from the University of Oregon with a Bachelor of Arts in Political Science with a specialization in Administration and Organization.\n \"We are thrilled to have Erik join the Marina Biotech team to establish a sales and marketing capability for Prestalia. In addition, he will play a key role in developing the commercial strategies for our other therapies if they receive regulatory approvals,\" stated Joseph Ramelli, CEO of Marina Biotech. \"Our recent acquisition of the FDA approved therapy Prestalia represents a large and attractive market opportunity for Marina, which made finding the right Chief Commercial Officer essential. I am confident that Erik is that person.\"\n Mr. Emerson stated, \"The opportunity to work with the leadership at Mar...